Drug Type Biological products |
Synonyms IMM65, PORT3 |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Phase 2 | CA | 16 Jul 2021 | |
Ovarian Epithelial Carcinoma | Phase 2 | CA | 12 Jul 2021 | |
Solid tumor | Phase 1 | NL | 10 Jan 2021 |